Kidney Cancer Clinical Trials

Showing 1-15 of 15 items
1.
2.
3.
4.
  • A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
  • CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiation treatment. Currently, radiosurgery is commonly used for brain metastases, Stage I lung cancer, spine tumors, and localized prostate cancer. The purpose of this protocol is to evaluate the role of Radiosurgery for the treatment of clinically localized primary renal cell carcinoma.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
5.
6.
7.
  • Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
  • The main goal of the research study is to determine whether treating renal cell cancer patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of kidney cancer that has spread to other parts of the body, can make the cancer easier to kill and eliminate. Another goal is to see how the study drug affects the body's immune cells which fight cancer cells.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
8.
  • A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
  • This is a Phase 1b, open-label, multi-center, multiple-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D) of avelumab (MSB0010718C) in combination with axitinib (AG-013736). Once the MTD of avelumab administered in combination with axitinib is estimated (dose finding portion), the dose expansion phase will be opened to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarker modulation.
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
9.
10.
11.
  • A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
  • PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of PT2385 Tablets and/or the recommended Phase 2 dose (RP2D) of PT2385 Tablets in patients with advanced clear cell renal cell carcinoma (ccRCC). PART 2: The primary objective of this study is to identify the maximum tolerated dose (MTD) of PT2385 Tablets in combination with niovolumab up to the recommended Phase 2 dose (RP2D), in patients with advanced clear cell renal cell carcinoma (ccRCC).
  • Diagnoses: Kidney Cancer
  • Status: Recruiting
12.
13.
14.
15.
Showing 1-15 of 15 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms